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OBJECTIVES: Discontinuation or switch of antipsychotic treat-
ment is commonly seen in patients with schizophrenia. Treat-
ment discontinuation has been recognized as an important
outcome as it integrates patients’ and clinicians’ judgments of
efﬁcacy, safety, and tolerability into a global measure of effec-
tiveness. The objective of the current analysis is to assess the
difference in treatment discontinuation for patients with schizo-
phrenia treated with Risperidone Long-Acting Injection (RLAI)
versus those treated with oral antipsychotics (atypical and con-
ventional) enrolled in the electronic Schizophrenia Adherence
Registry (e-STAR) in Spain. METHODS: E-STAR is a secure,
web-based, international, long-term, prospective, observational
study of patients with schizophrenia who commence a new antip-
sychotic drug during their routine clinical management. Data
were collected retrospectively and prospectively. Time on treat-
ment was analysed using Kaplan-Meier analysis and propor-
tional hazards regression. RESULTS: A total of 1622 patients
were enrolled into e-STAR in Spain, 1345 were initiated on RLAI
and 277 on oral antipsychotics at baseline. RLAI treated patients
had signiﬁcantly longer average disease duration (12.9  9.5
years vs. 11.4  9.8, p = 0.0136) and were slightly older
(38.4  11.2 years vs. 37  10.8, p = 0.052) than oral antipsy-
chotic treated patients. By 24 months, signiﬁcantly higher
percent of RLAI patients than that of oral antipsychotic users
stayed on their original treatment as revealed by the Kaplan-
Meier survival analysis that 81.8% (95% conﬁdence interval
[CI] = 79.5–83.9) of RLAI patients versus 63.4% (CI = 56.9–
69.1) of oral antipsychotic patients (p < 0.0001)) still being
maintained on their original treatment. The multivariate propor-
tional hazards regression controlling patient difference showed
that discontinuation hazard ratio (HR) was 2.30 (CI = 1.79–
2.97, p < 0.0001) for oral antipsychotic users compared to RLAI
patients. CONCLUSION: The results from this 2-year prospec-
tive, observational trial show that patients treated with RLAI are
2.3 times more likely to remain on treatment than those treated
with oral antipsychotics.
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OBJECTIVES: To assess changes in illness severity (Clinical
Global Impression-Severity scale, CGI-S) and functioning
(Global Assessment of Functioning, GAF) in Belgian patients
initiated on risperidone long-acting injection (RLAI) during
routine clinical practice. METHODS: E-STAR is a secure web-
based, international, observational study of patients with
schizophrenia who have been initiated with RLAI. Data are
collected both retrospectively (1 year) and prospectively (2
years) every 3 months. Results presented in this report reﬂect
the current status of Belgian patients who have been followed
for at least 18 months. RESULTS: To date, 201 subjects have
been followed for at least 18-months. Most were male (62.7%)
with mean age of 40.3  13.0 years, with mean time since diag-
nosis of 9.4  9.1 years. At 18-months, 80.6% of patients
remained on RLAI treatment. Most frequent reasons for switch-
ing to RLAI were poor compliance on previous therapy
(43.3%), need for maintenance therapy (22.4%), and insufﬁ-
cient response on previous therapy (15.4%). Mean CGI-S score
at baseline was 4.6  1.0 indicating moderate to marked illness
severity. At 18 months, mean CGI-S score signiﬁcantly
decreased to 3.5  1.2 (p < 0.001) indicating mild to moderate
illness severity. Similarly the mean GAF score at baseline was
44.1  12.4 at baseline and improved signiﬁcantly to
58.2  14.2 at 18 months (p < 0.001). CONCLUSION: Signiﬁ-
cant improvements in disease severity and functioning during
18-month treatment with RLAI were observed in patients with
schizophrenia. Follow-up is ongoing until 24 months.
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OBJECTIVES: To assess illness remission in patients with schizo-
phrenia enrolled in the electronic-Schizophrenia Treatment
Adherence Registry (e-STAR) in Czech Republic and Slovakia.
METHODS: E-STAR is a secure web-based, ongoing, interna-
tional, long-term observational study of patients with schizo-
phrenia who initiate RLAI during routine clinical management.
Data is collected retrospectively (1 year) and prospectively (2
years). Prospectively patients are evaluated for the following
symptoms: delusions, conceptual disorganization, hallucinatory
behaviour, mannerisms and posturing, unusual thought content,
blunted affect, passive/apathetic social withdrawal, and lack of
spontaneity and ﬂow of conversation. Patients in whom all of
these symptoms are absent, minimal or mild and within normal
boundaries, stable, and do not interfere with thinking, social
relations, and behaviour or functioning, were considered to be in
cross-sectional remission and if this persisted for at least 6
months, they were considered to be in remission. RESULTS: To
date a combined total of 1068 patients have been enrolled into
e-STAR in Czech Republic and Slovakia; 280 patients have been
followed for at least 12-months (156 Czech Republic, 124 Slo-
vakia). Of the 280 patients, the majority were male (57.9%) with
a diagnosis of schizophrenia or schizoaffective disorder (85.7%,
14.3% respectively) with a mean age of 37  12.1 years and a
mean time since diagnosis of 9.2  9 years. The proportion of
patients who met the criteria for cross-sectional remission
increased from 2.4% at baseline to 37.9% at 12 months. After
12-months, 20.6% of patients met the criteria for illness remis-
sion. CONCLUSION: Based on 12-month interim results, the
proportion of patients who met the criteria for illness remission
increased after initiating RLAI.
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